Markus Georg Rudolph

Markus Georg Rudolph

Auto-generated profile, based on publicly available information

Markus Georg Rudolph

Therapeutic Modalities, Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2006 in Annual Review of Immunology
Verified
Journal Article
Closed access
MRMarkus G. Rudolph
Markus G. Rudolph
RSRobyn L. Stanfield
Robyn L. Stanfield
IWIan A. Wilson
Ian A. Wilson
Since the first crystal structure determinations of αβ T cell receptors (TCRs) bound to class I MHC-peptide (pMHC) antigens in 1996, a sizable database of 24 class I and class II TCR/pMHC complexes has been accumulated that now defines a substantial degree of structural variability in TCR/pMHC recognition. Recent determination of free and bound γδ TCR structures has enabled comparisons of the modes of antigen recognition by αβ and γδ T cells and antibodies. Crystal structures of TCR accessory (CD4, CD8) and coreceptor molecules (CD3ɛδ, CD3ɛγ) have further advanced our structural understanding of most of the components that constitute the TCR signaling complex. Despite all these efforts, the structural basis for MHC restriction and signaling remains elusive as no structural features that define a common binding mode or signaling mechanism have yet been gleaned from the current set of TCR/pMHC complexes. Notwithstanding, the impressive array of self, foreign (microbial), and autoimmune TCR complexes have uncovered the diverse ways in which antigens can be specifically recognized by TCRs.

1 February 2002 in Current Opinion in Immunology
Verified
Journal Article
Closed access
MRMarkus G Rudolph
Markus G Rudolph
IWIan A Wilson
Ian A Wilson

18 May 2009 in Journal of Cell Biology
Verified
Journal Article
Open access
ABAnna V. Bulankina
Anna V. Bulankina
ADAnke Deggerich
Anke Deggerich
DWDirk Wenzel
Dirk Wenzel
KMKudzai Mutenda
Kudzai Mutenda
JWJulia G. Wittmann
Julia G. Wittmann
SHStefan Höning
Stefan Höning
TIP47 (tail-interacting protein of 47 kD) was characterized as a cargo selection device for mannose 6-phosphate receptors (MPRs), directing their transport from endosomes to the trans-Golgi network. In contrast, our current analysis shows that cytosolic TIP47 is not recruited to organelles of the biosynthetic and endocytic pathways. Knockdown of TIP47 expression had no effect on MPR distribution or trafficking and did not affect lysosomal enzyme sorting. Therefore, our data argue against a function of TIP47 as a sorting device. Instead, TIP47 is recruited to lipid droplets (LDs) by an amino-terminal sequence comprising 11-mer repeats. We show that TIP47 has apolipoprotein-like properties and reorganizes liposomes into small lipid discs. Suppression of TIP47 blocked LD maturation and decreased the incorporation of triacylglycerol into LDs. We conclude that TIP47 functions in the biogenesis of LDs.

4 December 2017 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Open access
PDF file
ZGZied Gaieb
Zied Gaieb
SLShuai Liu
Shuai Liu
SGSymon Gathiaka
Symon Gathiaka
MCMichael Chiu
Michael Chiu
HYHuanwang Yang
Huanwang Yang
RARommie Amaro
Rommie Amaro
The Drug Design Data Resource (D3R) ran Grand Challenge 2 (GC2) from September 2016 through February 2017. This challenge was based on a dataset of structures and affinities for the nuclear receptor farnesoid X receptor (FXR), contributed by F. Hoffmann-La Roche. The dataset contained 102 IC50 values, spanning six orders of magnitude, and 36 high-resolution co-crystal structures with representatives of four major ligand classes. Strong global participation was evident, with 49 participants submitting 262 prediction submission packages in total. Procedurally, GC2 mimicked Grand Challenge 2015 (GC2015), with a Stage 1 subchallenge testing ligand pose prediction methods and ranking and scoring methods, and a Stage 2 subchallenge testing only ligand ranking and scoring methods after the release of all blinded co-crystal structures. Two smaller curated sets of 18 and 15 ligands were developed to test alchemical free energy methods. This overview summarizes all aspects of GC2, including the dataset details, challenge procedures, and participant results. We also consider implications for progress in the field, while highlighting methodological areas that merit continued development. Similar to GC2015, the outcome of GC2 underscores the pressing need for methods development in pose prediction, particularly for ligand scaffolds not currently represented in the Protein Data Bank (http://www.pdb.org), and in affinity ranking and scoring of bound ligands.

1 March 2000 in Immunity
Verified
Journal Article
Closed access
MDMassimo Degano
Massimo Degano
KGK.CHristopher Garcia
K.CHristopher Garcia
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
MRMarkus G Rudolph
Markus G Rudolph
LTLuc Teyton
Luc Teyton
IWIan A Wilson
Ian A Wilson

1 May 2005 in Cell
Verified
Journal Article
Closed access
TDThomas Dierks
Thomas Dierks
ADAchim Dickmanns
Achim Dickmanns
APAndrea Preusser-Kunze
Andrea Preusser-Kunze
BSBernhard Schmidt
Bernhard Schmidt
MMMalaiyalam Mariappan
Malaiyalam Mariappan
MRMarkus Georg Rudolph
Markus Georg Rudolph